Olema Pharmaceuticals Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
IPO Year: 2020
Exchange: NASDAQ
Website: olema.com
Peers
Recent Analyst Ratings for Olema Pharmaceuticals Inc.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/2/2024 | $24.00 | Buy | Goldman |
1/30/2024 | $20.00 | Buy | Citigroup |
7/21/2023 | $21.00 | Outperform | Oppenheimer |
5/5/2023 | $16.00 | Overweight | CapitalOne |
2/22/2023 | $12.00 | Outperform | Credit Suisse |
7/6/2022 | $16.00 | Buy | Canaccord Genuity |
6/9/2022 | $12.00 | Neutral → Buy | H.C. Wainwright |
2/28/2022 | Neutral | HC Wainwright & Co. | |
12/7/2021 | Outperform | Cowen |
Olema Pharmaceuticals Inc. Press Releases
Fastest customizable press release news feed in the world
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a poster highlighting preclinical anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell lung cancer models in a late-breaking session at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois. Poster Presentati
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in 2026Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in patients with frontline metastatic breast cancer enabled by new Novartis collaboration and $250 million equity private placement; trial on track for initiation this yearPromising updated results from the ongoing Phase 1b/2 study of palazestrant in combination with ribociclib in patients with ER+/HER2- advanced or metastatic breast cancer presented at SABCS in December 2024; updated mPFS presented at the TD Cowen Health Care Conference in March 2025; mature data expected
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
SAN FRANCISCO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 10:30 a.m. ET. A live webcast of the presentation and any accompanying materials will be available under the Events and Presentations section of Olema's Investor Relations website at ir.olema.com. A recording of the presentation will be
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary. "We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late-stage palazestrant programs and our OP-3136 KAT6 program through clinical development," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "Her extensive e
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 285,000 shares of the Company's common stock, effective as of February 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordanc
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that management will participate in the following investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceDate: Wednesday, February 12, 2025 at 9:20 a.m. ETFormat: Virtual Presentation Citi's 2025 Virtual Oncology Leadership SummitDate: Thursday, February 20, 2025 at 10 a.m. ETFormat: Virtual Fireside Chat Live webcasts of these presentations will be available in the
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to three new employees to purchase an aggregate of 26,200 shares of the Company's common stock, effective as of January 2, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordanc
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14, 2025 at 3:45 p.m. PT (6:45 p.m. ET). A live webcast of the presentation and any accompanying materials will be available under the Events and Presentations section of Olema's Investor Relations website at ir.olema.com.
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer With a median follow-up of 12 months, median progression-free survival (PFS) has not been reached6-month PFS rate was 73% in all patients, 81% in patients with ESR1 mutations, 70% in ESR1 wild-type patients, and 68% in patients with prior CDK4/6 inhibitor treatment; data continue to mature Conference call today at 8:00 a.m. ET SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA),
Olema Pharmaceuticals Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Goldman initiated coverage on Olema Pharmaceuticals with a new price target
Goldman initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $24.00
Citigroup initiated coverage on Olema Pharmaceuticals with a new price target
Citigroup initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $20.00
Oppenheimer initiated coverage on Olema Pharmaceuticals with a new price target
Oppenheimer initiated coverage of Olema Pharmaceuticals with a rating of Outperform and set a new price target of $21.00
CapitalOne initiated coverage on Olema Pharmaceuticals with a new price target
CapitalOne initiated coverage of Olema Pharmaceuticals with a rating of Overweight and set a new price target of $16.00
Credit Suisse initiated coverage on Olema Pharmaceuticals with a new price target
Credit Suisse initiated coverage of Olema Pharmaceuticals with a rating of Outperform and set a new price target of $12.00
Canaccord Genuity resumed coverage on Olema Pharmaceuticals with a new price target
Canaccord Genuity resumed coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $16.00
Olema Pharmaceuticals upgraded by H.C. Wainwright with a new price target
H.C. Wainwright upgraded Olema Pharmaceuticals from Neutral to Buy and set a new price target of $12.00
HC Wainwright & Co. initiated coverage on Olema Pharmaceuticals
HC Wainwright & Co. initiated coverage of Olema Pharmaceuticals with a rating of Neutral
Cowen resumed coverage on Olema Pharmaceuticals
Cowen resumed coverage of Olema Pharmaceuticals with a rating of Outperform
Olema Pharmaceuticals Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Large owner Bain Capital Life Sciences Investors, Llc bought $1,727,370 worth of shares (300,000 units at $5.76) and disposed of 3,500,000 shares (SEC Form 4)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
Amendment: Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) and bought $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)
4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
Graham G. Walmsley bought $6,871,279 worth of shares (640,000 units at $10.74) (SEC Form 4)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
Paradigm Biocapital Advisors Lp bought $1,160,000 worth of shares (100,000 units at $11.60) (SEC Form 4)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
Olema Pharmaceuticals Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SEC Form 4 filed by CH. DISCOV. & NON-CLIN DEV OFF Myles David C.
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
SEC Form 4 filed by CHIEF MEDICAL OFFICER Zojwalla Naseem
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
SEC Form 4 filed by CHIEF LEGAL OFFICER Mitchell Shawnte
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
SEC Form 4 filed by CH. OPERATING & FINANCIAL OFF. Kovacs Shane William Charles
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
SEC Form 4 filed by PRESIDENT AND CEO Bohen Sean
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
SEC Form 3 filed by new insider Mitchell Shawnte
3 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
See Explanation of Responses Bvf Partners L P/Il returned 420,000 shares to the company (SEC Form 4)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
Large owner Bain Capital Life Sciences Investors, Llc bought $1,727,370 worth of shares (300,000 units at $5.76) and disposed of 3,500,000 shares (SEC Form 4)
4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
New insider Bain Capital Life Sciences Investors, Llc claimed ownership of 7,500,000 shares (SEC Form 3)
3 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
Amendment: Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) and bought $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)
4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
Olema Pharmaceuticals Inc. SEC Filings
SEC Form S-8 filed by Olema Pharmaceuticals Inc.
S-8 - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
SEC Form 10-K filed by Olema Pharmaceuticals Inc.
10-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
Olema Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
Olema Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
SEC Form EFFECT filed by Olema Pharmaceuticals Inc.
EFFECT - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
SEC Form EFFECT filed by Olema Pharmaceuticals Inc.
EFFECT - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
SEC Form 424B5 filed by Olema Pharmaceuticals Inc.
424B5 - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
SEC Form 424B3 filed by Olema Pharmaceuticals Inc.
424B3 - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
Olema Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
SEC Form 8-K filed by Olema Pharmaceuticals Inc.
8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
Olema Pharmaceuticals Inc. Leadership Updates
Live Leadership Updates
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary. "We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late-stage palazestrant programs and our OP-3136 KAT6 program through clinical development," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "Her extensive e
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarterNew clinical data for palazestrant (OP-1250) in combination with CDK4/6 inhibitors to be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) in December Strong cash, cash equivalents and marketable securities position of $276.9 million as of September 30, 2023 SAN FRANCISCO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancer
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced the appointment of Scott Garland to the company's Board of Directors. Mr. Garland brings more than 30 years of biopharmaceutical industry experience with deep commercial and executive leadership expertise. "We are delighted to have Scott join our Board of Directors at such an exciting time for Olema," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "His broad experien
Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer
• Dr. Zojwalla brings extensive and diverse experience in clinical development and regulatory strategy for novel oncology therapies • As part of planned leadership transition, former CMO Pamela Klein, M.D., will become a senior advisor and member of Olema's Scientific Advisory Board SAN FRANCISCO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced the appointment of Naseem Zojwalla, M.D., as Chief Medical Officer. Bringing more than 15 years of oncology and clinical deve
Olema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors
Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its PipelineLongstanding Olema Director Dr. Frank McCormick to Transition from Board of Directors and Return to His Position as Chairman of Olema’s Scientific Advisory Board SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the appointment of Yi Larson to the company’s Board of Directors, and the transition of lon
Olema Pharmaceuticals Inc. Financials
Live finance-specific insights
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer With a median follow-up of 12 months, median progression-free survival (PFS) has not been reached6-month PFS rate was 73% in all patients, 81% in patients with ESR1 mutations, 70% in ESR1 wild-type patients, and 68% in patients with prior CDK4/6 inhibitor treatment; data continue to mature Conference call today at 8:00 a.m. ET SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA),
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it will present new data from the Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10-13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Poster Details Title: A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patien
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted the
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclibNew clinical data from palazestrant-ribociclib combination study to be presented at the ESMO Breast Cancer Annual Congress 2024 in Berlin, Germany. Olema will host an investor conference call on May 15, 2024, at 8:00 a.m. ET to review the dataInvestigational New Drug (IND) application for OP-3136, a novel KAT6 inhibitor, expected to be filed with FDA in late 2024Cash, cash equivalents and marketable securities of $249.0 million as of March 31, 2024 SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that it will present new clinical data from the Company's ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibitor ribociclib in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress 2024 taking place May 15-17, 2023, in Berlin, Germany. Details of the ESMO Breast Cancer Annual Congress 2024 poster presentation are: Title:
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile consistent with the FDA-approved labels of ribociclib or palbociclib plus an endocrine therapyOPERA-01 trials-in-progress poster outlines Phase 3 trial design; clinical sites activated and enrolling with first patient dosed in November 2023Olema will host an investor conference call at 8:00 a.m. ET on December 6, 2023 SAN FRANCISCO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on t
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023 Olema will host an investor conference call at 8:00 a.m. ET on Dec. 8, 2023 SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that it will be presenting new Phase 1b/2 cli
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52% In an analysis of 49 second- and third-line patients, the median PFS was 7.2 months with a CBR of 48%; the median PFS was 7.3 months with a CBR of 59% in patients with ESR1 mutations Results support continued development of palazestrant in the OPERA-01 monotherapy Phase 3 pivotal trialOlema will host an investor conference call at 8:00 a.m. ET on Monday, October 23, 2023 SAN FRANCISCO, Oct. 22, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", or the "Company", NASDAQ:OLMA),
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor conference call at 8:00 a.m. ET on October 23, 2023 SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced an oral presentation on the Phase 2 monotherapy study results of palazestrant (OP-1250), the Company's complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) for the treatme
Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial
OP-1250 continues to demonstrate favorable tolerability, high drug exposure, and strong anti-tumor activity in preliminary Phase 1/2 study results presented at the 34th EORTC-NCI-AACR SymposiumInitial clinical data for OP-1250 in combination with CDK 4/6 inhibitor palbociclib expected in the fourth quarter of 2022Pivotal monotherapy Phase 3 study planned for initiation mid-2023Company to host investor conference call today at 8:00 a.m. ET SAN FRANCISCO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology" or the "Company", NASDAQ:OLMA) today announced preliminary clinical results from a Phase 1/2 clinical study of OP-1250, the Company's complete est
Olema Pharmaceuticals Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G filed by Olema Pharmaceuticals Inc.
SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.
SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
Amendment: SEC Form SC 13G/A filed by Olema Pharmaceuticals Inc.
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
Amendment: SEC Form SC 13G/A filed by Olema Pharmaceuticals Inc.
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SEC Form SC 13G filed by Olema Pharmaceuticals Inc.
SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc. (Amendment)
SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SEC Form SC 13G filed by Olema Pharmaceuticals Inc.
SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SEC Form SC 13G/A filed by Olema Pharmaceuticals Inc. (Amendment)
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SEC Form SC 13G/A filed by Olema Pharmaceuticals Inc. (Amendment)
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
SEC Form SC 13G/A filed by Olema Pharmaceuticals Inc. (Amendment)
SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)